(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.18%.
Lipocine's earnings in 2026 is -$11,434,526.On average, 4 Wall Street analysts forecast LPCN's earnings for 2026 to be -$16,019,408, with the lowest LPCN earnings forecast at -$15,431,593, and the highest LPCN earnings forecast at -$16,447,285. On average, 3 Wall Street analysts forecast LPCN's earnings for 2027 to be -$13,875,078, with the lowest LPCN earnings forecast at -$13,330,957, and the highest LPCN earnings forecast at -$14,283,168.
In 2028, LPCN is forecast to generate -$7,988,681 in earnings, with the lowest earnings forecast at -$7,675,400 and the highest earnings forecast at -$8,223,642.